DA-9601 for erosive gastritis: Results of a double-blind placebo-controlled phase III clinical trial

Figure 1 Estimated cure rates of erosive gastritis by intention-to-treat (ITT) analysis among patients treated with DA-9601 (180 mg or 360 mg, t. i.d.) or cetraxate (600 mg, t.i.d.) for 2 wk. ^aP < 0.05 vs 600 mg of cetraxate.

Figure 2 Estimated cure rates of erosive gastritis by per proto-col (PP) analysis among patients treated with DA-9601 (180 mg or 360 mg, t. i.d.) or cetraxate (600 mg, t.i.d.) for 2 wk. ^aP < 0.05 vs 600 mg of cetraxate.

Figure 3 Estimated improvement rates of erosive gastritis by intention-to-treat (ITT) analysis among patients treated with DA-9601 (180 mg or 360 mg, t. i.d.) or cetraxate (600 mg, t.i.d.) for 2 wk. ^aP < 0.05 vs 600 mg of cetraxate.

Figure 4 Estimated improvement rates of erosive gastritis by per protocol (PP) analysis among patients treated with DA-9601 (180 mg or 360 mg, t. i.d.) or cetraxate (600 mg, t.i.d.) for 2 wk. ^aP < 0.05 vs. 600 mg of cetraxate.

Figure 5 Overall reduction rates of symptoms among patients treated with cetraxate (600 mg, t. i.d.) or DA-9601 (180 mg and 360 mg, t.i.d.) for 2 wk.